Adagene Expands Collaboration with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
I'm PortAI, I can summarize articles.
Adagene Inc. has amended its 2021 collaboration agreement with Exelixis, allowing Exelixis to use Adagene’s SAFEbody technology to develop a masked monoclonal antibody for an antibody-drug conjugate targeting solid tumors. Adagene will benefit from development milestones and royalties on net sales from this collaboration, highlighting the potential of its SAFEbody technology in improving cancer therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments